Literature DB >> 22602825

Dermatomyositis and chest radiography leading to the diagnosis of lung cancer and subsequent confusions in staging due to the presence of tuberculosis.

Swaroop Revannasiddaiah1, Manoj Kumar Gupta, Madhup Rastogi, Avinash Arjun Rao Kesari, Rajeev Kumar Seam, Manish Gupta, Suneel Chauhan, Irappa Madabhavi.   

Abstract

This clinical scenario describes dermatomyositis as a presenting feature of carcinoma of the lung. However, the coincident existence of tuberculosis in the opposite lung gave rise to a false impression of contralateral lung metastasis and hence confusions with regard to staging ensued, which were clarified after further investigation confirmed a unilateral lung adenocarcinoma and contralateral tuberculosis. The patient was initiated on oral antiepidermal growth factor receptor therapy with erlotinib, as well as on multi-drug therapy for tuberculosis. This report intends to illustrate that paraneoplastic syndromes such as dermatomyositis can be the presenting feature of lung cancer, and also that the co-incident presence of carcinoma and tuberculosis can cause confusions with regard to staging and management.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22602825      PMCID: PMC3339164          DOI: 10.1136/bcr.01.2012.5585

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  27 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

3.  The MRC breathlessness scale.

Authors:  Chris Stenton
Journal:  Occup Med (Lond)       Date:  2008-05       Impact factor: 1.611

4.  Revised National Tuberculosis Control Programme (RNTCP).

Authors:  A Muruganathan; Aleyamma Thomas; M Muniyandi; V Chandrasekaran
Journal:  J Indian Med Assoc       Date:  2010-12

5.  Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.

Authors:  C L Hill; Y Zhang; B Sigurgeirsson; E Pukkala; L Mellemkjaer; A Airio; S R Evans; D T Felson
Journal:  Lancet       Date:  2001-01-13       Impact factor: 79.321

6.  Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis.

Authors:  Albert Selva-O'Callaghan; Josep M Grau; Cristina Gámez-Cenzano; Antonio Vidaller-Palacín; Xavier Martínez-Gómez; Ernesto Trallero-Araguás; Eduard Andía-Navarro; Miquel Vilardell-Tarrés
Journal:  Am J Med       Date:  2010-06       Impact factor: 4.965

Review 7.  Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.

Authors:  Peggy A Wu; Yevgeniy Balagula; Mario E Lacouture; Milan J Anadkat
Journal:  Curr Opin Oncol       Date:  2011-07       Impact factor: 3.645

8.  Pulmonary tuberculosis increases the risk of lung cancer: a population-based cohort study.

Authors:  Chen-Yi Wu; Hsiao-Yun Hu; Cheng-Yun Pu; Nicole Huang; Hsi-Che Shen; Chung-Pin Li; Yiing-Jeng Chou
Journal:  Cancer       Date:  2010-09-30       Impact factor: 6.860

9.  The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations.

Authors:  Isamu Okamoto; Tetsuya Mitsudomi; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Ther Adv Med Oncol       Date:  2010-09       Impact factor: 8.168

10.  The management of EGFR inhibitor adverse events: a case series and treatment paradigm.

Authors:  Amelia M Wnorowski; Aieska de Souza; Abraham Chachoua; David E Cohen
Journal:  Int J Dermatol       Date:  2012-02       Impact factor: 2.736

View more
  1 in total

1.  Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report.

Authors:  Andrew J Beel; David S Demos; Alfred Chung; Charles Liao; Natalie S Lui
Journal:  J Cardiothorac Surg       Date:  2018-02-07       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.